Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2025 investor letter. A ...

The ELITE arterial study demonstrated ease of use for Vivasure's PerQseal Elite with no need for pre-close.

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices. Boston-based Haemonetics, which is ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - specialty stocks, ...

Investors may be wondering whether Haemonetics at around US$74 is offering value right now, or whether the market is still undecided about its future potential. The stock has been quite mixed lately, ...

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...

The London Company, an investment management company, released “The London Company Small Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities ...

BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the ...

Shares of blood products company Haemonetics (NYSE:HAE). fell 2.1% in the morning session after Citigroup downgraded the stock to "Neutral" from "Buy." The action came from analyst Joanne Wuensch.

BOSTON, Oct. 6, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, ...

Haemonetics (NYSE:HAE) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...